In Deals With Respivert And Orexo, J&J's Respiratory Push Gets Going
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J acquired respiratory drug discovery firm Respivert and licensed two respiratory preclinical research programs from Orexo.
You may also be interested in...
Janssen Builds A Pulmonary Pipeline: An Interview With Sue Dillon
Citing high unmet medical need and significant commercial opportunity, Janssen Research & Development has dived into pulmonary therapeutics. TA head of immunology Sue Dillon discusses the rationale, the indications and the therapeutic approaches the company is taking.
Imperial Innovations Raises £140 Million To Invest In University Spin-Outs
The AIM-listed tech transfer group will increase its early-stage investments in spin-outs from Imperial College and three other top UK universities
Imperial Innovations Raises £140 Million To Invest In University Spin-Outs
The AIM-listed tech transfer group will increase its early-stage investments in spin-outs from Imperial College and three other top UK universities